Therapy News and Research

RSS

Submission of NDA for Istradefylline(KW-6002), an investigational anti-Parkinson's disease drug

Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.

30 Apr 2007

Cellular protein found that interferes with hepatitis C virus replication

Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus.

30 Apr 2007

New test for liver disease

A researcher at the Stanford University School of Medicine has helped confirm the reliability of a new test for liver disease that is ushering in the long-promised era of personalized medicine based on each individual's genetic makeup.

30 Apr 2007

Resistance training gets employees with rotator cuff injuries back to work

Resistance training, some of it job-specific, was successful in getting 90 percent of workers with severe rotator cuff injuries back to work, the majority (75 percent) at their previous job, after traditional physical therapy had failed to do so.

30 Apr 2007

FDA approves INVEGA treatment for schizophrenia

The U.S. Food and Drug Administration (FDA) has approved INVEGA (paliperidone) Extended-Release Tablets, a new once-daily, atypical antipsychotic, for the long-term maintenance treatment of schizophrenia.

30 Apr 2007

FDA approves new treatment for von Willebrand disease

The U.S. Food and Drug Administration (FDA) has approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).

30 Apr 2007

Link found between bile duct obstruction and bile duct cancer

When bile duct cancer cells were placed in the liver of animals with bile duct obstruction, they grew more rapidly than identical cells placed in animals without bile duct obstruction.

30 Apr 2007

Aspirin appears to be less effective heart treatment for women than men

A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.

30 Apr 2007

BioElectronics Corporation introduces new eye surgery recovery mask

BioElectronics Corporation (BIEL) has announced that its specially designed eye mask for placement of ActiPatch Therapy after blepharoplasty surgery is now available.

30 Apr 2007

Small amounts of stem/progenitor cells from bone marrow enhance repair of damaged tissues

New studies in the laboratory of Dr. Darwin J. Prockop, Director of Tulane University's Center for Gene Therapy, are shedding light on the previously mysterious mechanism through which even relatively small amounts of stem/progenitor cells taken from a patient's own bone marrow enhance repair of damaged tissues.

30 Apr 2007

Keeping the mind busy and occupied restores memories lost to dementia

Scientists in the U.S. believe that mental stimulation along with drug therapy may help people with diseases such as Alzheimer's and dementia regain some of their lost memories.

30 Apr 2007

Potential new treatment for desmoid fibromatosis

New hope is available for children who have a tumor called desmoid fibromatosis, according to results of a national clinical trial that was led by a St. Jude researcher.

27 Apr 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Sangamo BioSciences starts phase 2 trial of therapy diabetic neuropathy

Sangamo BioSciences has announced that the company has initiated a repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN).

27 Apr 2007

New mechanism identified for resistance to targeted lung cancer drugs

An international research team, led by investigators from the Massachusetts General Hospital (MGH) Cancer Center and Dana-Farber Cancer Institute (DFCI), has found a new way that some lung tumors become resistant to treatment with targeted therapy drugs like Iressa and Tarceva.

27 Apr 2007

Drug therapy can reduce preterm births and decrease lifetime medical costs

Researchers from MetroHealth Medical Center and Case Western Reserve University in Cleveland, OH found that treating expectant mothers who have had previous spontaneous preterm births with 17 Alpha Hydroxyprogesterone caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring by $2 billion per year.

27 Apr 2007